Barriers to clinical trial enrollment in racial and ethnic minority patients with cancer

391Citations
Citations of this article
334Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Clinical trials that study cancer are essential for testing the safety and effectiveness of promising treatments, but most people with cancer never enroll in a clinical trial - a challenge exemplified in racial and ethnic minorities. Underenrollment of racial and ethnic minorities reduces the generalizability of research findings and represents a disparity in access to high-quality health care. Methods: Using a multilevel model as a framework, potential barriers to trial enrollment of racial and ethnic minorities were identified at system, individual, and interpersonal levels. Exactly how each level directly or indirectly contributes to doctor-patient communication was also reviewed. Selected examples of implemented interventions are included to help address these barriers. We then propose our own evidence-based intervention addressing barriers at the individual and interpersonal levels. Results: Barriers to enrolling a diverse population of patients in clinical trials are complex and multilevel. Interventions focused at each level have been relatively successful, but multilevel interventions have the greatest potential for success. Conclusion: To increase the enrollment of racial and ethnic minorities in clinical trials, future interventions should address barriers at multiple levels.

Cite

CITATION STYLE

APA

Hamel, L. M., Penner, L. A., Albrecht, T. L., Heath, E., Gwede, C. K., & Eggly, S. (2016). Barriers to clinical trial enrollment in racial and ethnic minority patients with cancer. Cancer Control, 23(4), 327–337. https://doi.org/10.1177/107327481602300404

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free